The trial compared the use of i-FACTOR bone graft and autograft for ACDF procedures, and the outcomes were found to be statistically similar. Additionally, i-FACTOR achieved an 89 percent fusion rate whereas the autograft achieved a fusion rate of 85 percent. The data for the IDE and the results are being finalized for submission to the FDA.
Cerapedics is an orthobiologics company focused on developing and marketing peptide enhanced bone graft products based on its proprietary synthetic small peptide technology platform.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws
